APHIS Veterinary Biologics Program

Every animal vaccine, diagnostic test kit, antitoxin, and biological immunology product used in the United States — for livestock, poultry, companion animals, fish, or wildlife — must be licensed by USDA's Animal and Plant Health Inspection Service (APHIS) before it reaches your vet's shelf. The governing law is the Virus-Serum-Toxin Act of 1913 (VSTA), codified at 21 U.S.C. §§ 151–159, and the regulatory framework lives at 9 CFR Parts 101–124. APHIS's Center for Veterinary Biologics (CVB) runs the program from its Ames, Iowa campus. This is the veterinary equivalent of FDA's biologics licensing pathway — but older, administered by a different agency, and anchored in an entirely different statute.

Current Rule (2026)

What "Veterinary Biologic" Means

The statutory definition at 21 U.S.C. § 151 covers any virus, serum, toxin, or analogous product intended for use in the diagnosis, treatment, or prevention of diseases of animals. In practice, that includes:

• Vaccines: live, modified-live, killed, and recombinant vaccines for animal diseases (rabies, distemper, Newcastle disease, foot-and-mouth disease, bluetongue, salmonella, and dozens more)
• Bacterins and bacterial extracts: killed bacterial preparations for active immunization
• Diagnostic test kits: in-vitro reagents for detecting infection or immunity in animals
• Antitoxins and immune globulin products: passive immunization products
• Allergenic extracts: products used to test for and treat allergies in animals
• Genetically engineered immunizing products: recombinant vector vaccines, DNA vaccines, monoclonal antibody preparations

The key boundary with FDA: animal drugs (pharmaceutical chemicals like antibiotics) are FDA's province under the Federal Food, Drug, and Cosmetic Act; animal biologics (immunological products) are USDA APHIS's province under VSTA. The line is occasionally fuzzy — combination products containing both a drug and a biologic require inter-agency coordination — but the division has been stable since VSTA's enactment.

Key Mechanics

The APHIS Veterinary Biologics Program is built on three interlocking control points that apply to every licensed product throughout its entire lifecycle.

1. Pre-market dual licensing. Under 9 CFR 102, a company seeking to sell veterinary biologics needs two separate USDA licenses: an establishment license (covering the manufacturing facility itself) and a product license (covering each specific product). The facility license requires demonstrating that buildings, equipment, personnel qualifications, environmental controls, and biocontainment levels are appropriate for the agents being produced — detailed at 9 CFR 108. The product license requires submitting a complete "Outline of Production" — the binding master specification — along with Master Seed Virus or Master Cell Stock characterizations and results from three consecutive pre-licensing serials that pass all required tests. Every label must also receive APHIS approval before the product ships; see APHIS Veterinary Biologic Labeling and Records for the full label approval and recordkeeping requirements at 9 CFR 112 and 116. Any deviation from the approved Outline after licensing requires APHIS pre-approval before implementation.

2. Serial release testing. Even after licensing, every production lot (called a "serial") must pass mandatory tests before it can ship. The producer runs the tests prescribed in 9 CFR Part 113 — purity, safety, potency, and identity — submits results to APHIS CVB, and may not distribute the serial until cleared. For higher-risk products, APHIS may require submission of the actual serial for independent government testing rather than accepting the manufacturer's own results. Part 113's 118 sections specify the exact assay methods, pass/fail thresholds, and reference standards by product type: § 113.106 governs the live infectious bovine rhinotracheitis (IBR) vaccine potency assay; § 113.114 covers bovine viral diarrhea (BVD) vaccine; §§ 113.215–113.310 cover inactivated bacterins by target organism.

3. Post-market surveillance. Licensure doesn't end APHIS's oversight. Under 9 CFR 116.5–116.7, licensees must report serious adverse events — animal deaths, vaccine reactions, breakthrough infections — within 14 days of discovery. APHIS field inspectors conduct routine facility inspections every one to three years. APHIS can require recall of any serial failing post-release testing, and can suspend or revoke establishment or product licenses for violations. The combination makes the program genuinely continuous rather than a one-time approval gate.

4. Import permits. Biological products manufactured outside the United States require a USDA APHIS import permit under 9 CFR 104 in addition to country-of-origin licensure. This gives APHIS visibility into foreign-manufactured products entering U.S. animal health supply chains — a material consideration given that some vaccine ingredients and complete products are sourced from European, Latin American, and Asian facilities. The permit requirement works alongside APHIS's animal import quarantine rules and the recognition of foreign animal health regions — APHIS's disease-status assessment of foreign countries directly shapes what import conditions and product requirements apply.

The Genetically Engineered Vaccine Pathway

Recombinant vector vaccines, DNA vaccines, and monoclonal antibody preparations receive heightened regulatory review under 9 CFR 105 and 9 CFR 116:

• Master Seed characterization must include sequencing of the genetic insert, not just biological characterization
• Containment requirements during production scale with the biocontainment level of the parent organism (not the modified product alone)
• Environmental release studies are required for any vaccine intended for use in wildlife or distributed as oral baits — the oral rabies vaccine bait programs for raccoons and coyotes that operate in roughly 30 states require this review
• NEPA environmental assessment applies when significant environmental impacts are possible

The oral wildlife rabies program is the highest-profile example: APHIS coordinates with state wildlife agencies to distribute Raboral V-RG (a vaccinia-vectored product) and ONRAB (an adenovirus-vectored product) as edible baits. Each distribution event triggers an environmental review and requires APHIS-licensed product.

Postmarket Surveillance

After a product is licensed, APHIS CVB continues active oversight through:

• Adverse event reporting (9 CFR 116.5–116.7): licensees must report adverse events (animal deaths, vaccine reactions, breakthrough infections, drug-resistance emergence) to APHIS within 14 days of discovery for serious events
• Inspection program: APHIS field inspectors conduct routine on-site facility inspections, typically every 1–3 years per establishment
• Product recalls: APHIS can require recall of any serial that fails post-release testing or that's associated with adverse events suggesting a quality defect
• License modifications and suspensions: APHIS can modify, suspend, or revoke an establishment or product license for violations

How It Affects You

If you're a livestock producer, dairy farmer, or poultry operator: every vaccine you administer to your herd or flock is USDA-licensed under this program. The label is legally required to state the species and age the product is approved for, the route of administration, and the claimed duration of immunity. Off-label use — for example, using a bovine product in a bison herd, or doubling the dose — is permitted only under a licensed veterinarian's direction. Vaccines required for interstate movement (bovine brucellosis, equine infectious anemia testing) flow through APHIS's broader Animal Health Protection regulatory framework; those programs rely on CVB-licensed biologics as their official tools. The HPAI (highly pathogenic avian influenza) outbreak that swept U.S. poultry flocks in 2022–2025 and ultimately crossed into dairy cattle accelerated USDA evaluation of licensed HPAI vaccines — products that must clear this program before any commercial rollout.

If you have a companion animal: every vaccine your dog or cat receives — DA2PP (distemper, adenovirus, parvovirus, parainfluenza), rabies, FVRCP (feline rhinotracheitis, calicivirus, panleukopenia), leptospirosis, Bordetella — is USDA-licensed for the specific species and age range your vet is treating. If your pet has a reaction to a vaccine, your vet can (and should) report it to APHIS CVB through the online adverse event reporting system. Reported reactions feed into APHIS's safety database and can trigger product recalls.

If you work in animal biologics: facility licensure, product licensure, and serial testing are the three non-negotiable compliance pillars. The Outline of Production is not merely documentation — it is the binding production specification. Any change in raw materials, manufacturing equipment, testing methodology, or production scale requires APHIS review and approval before implementation. A silent change — even one that improves the product — constitutes a violation. Budget 6 to 18 months for Outline amendment review on significant changes. The Master Seed Virus / Master Cell Stock system means your quality traceability goes back to a single characterized biological ancestor; every production serial must trace to that seed within an approved number of passages.

If you're a researcher working with veterinary pathogens: products used solely for research are typically exempt from licensure requirements. However, materials shipped between facilities — especially foreign animal disease agents (foot-and-mouth disease, classical swine fever, African swine fever) or BSL-3+ pathogens — may require APHIS permits under 9 CFR Parts 121–122, which govern select agent and toxin regulations. These are separate from CVB's biologics program but enforced by the same agency.

State Variations

• The Virus-Serum-Toxin Act is federally preemptive for the licensure, distribution, and labeling of veterinary biologics in interstate commerce. States cannot impose additional federal-style product licensing requirements on top of USDA's.
• States retain authority over the practice of veterinary medicine — state veterinary boards regulate who can administer vaccines, prescribing authority, compounding, and disposal of biological waste.
• California, Nevada, and Hawaii impose animal entry requirements that include specific vaccination histories — those requirements reference federally licensed products as the standard.
• Several states require rabies vaccination documentation (using USDA-licensed products) as a condition of dog licensing. Some states require brucellosis vaccination for cattle crossing state lines.

Legal Authority

The APHIS Veterinary Biologics Program traces its authority directly to the Virus-Serum-Toxin Act of 1913 — the oldest federal biologics statute in U.S. law, predating FDA's drug approval authority by decades:

• 21 U.S.C. § 151 — Core prohibition: no person or establishment may prepare, sell, barter, or ship any virus, serum, toxin, or analogous product for treating domestic animals that is worthless, contaminated, dangerous, or harmful. Preparation must occur at a licensed establishment in compliance with USDA rules.
• 21 U.S.C. § 152 — Import control: no veterinary biologic may enter the United States unless it meets USDA standards and the importer holds the required permit; worthless, contaminated, dangerous, or harmful products are categorically excluded. Source: staging DB, usc_sections table.
• 21 U.S.C. § 153 — Inspection of imports: the Secretary of Agriculture may direct Bureau of Animal Industry officers to inspect any biological product offered for import; products found deficient may be denied entry and destroyed at the importer's expense.
• 21 U.S.C. § 154 — Regulatory authority: the Secretary may issue rules governing the preparation, sale, and shipment of veterinary biologics and may issue, suspend, revoke, or condition licenses for establishments and products — the statutory hook for all of 9 CFR Parts 101–124.
• 21 U.S.C. § 155 — Import permits: establishes the permit system for importing foreign-manufactured veterinary biologics (implemented at 9 CFR 104).
• 21 U.S.C. § 156 — License conditions: every establishment license must permit USDA inspection of facilities, products, and production methods. After a hearing, APHIS may suspend any license for violations.
• 21 U.S.C. § 157 — Inspection authority: USDA officers authorized by the Secretary may inspect, at any hour of the day or night, any establishment manufacturing veterinary biologics for sale, trade, or interstate shipment.
• 21 U.S.C. § 158 — Penalties: violations of VSTA are misdemeanors punishable by up to a $1,000 fine, up to one year imprisonment, or both.
• 21 U.S.C. § 159 — Enforcement and Congressional findings: enforcement follows procedures at 21 U.S.C. §§ 672–674; Congress found that veterinary biologics in interstate/foreign commerce require federal oversight to protect animal health and the national agricultural economy.
• 21 U.S.C. § 113a — Research authority: the Secretary may establish research laboratories, purchase land and buildings, and enter research contracts to study foot-and-mouth disease and other animal diseases threatening U.S. livestock; live foot-and-mouth virus may not enter the U.S. mainland without a USDA permit and protective measures.

Recent Rulemakings

• December 2007 (72 FR 72564) — Major modernization of 9 CFR 113 standard requirements: updated potency assay methods, strengthened environmental release requirements for genetically engineered products, added stability testing requirements
• November 1991 (56 FR 66784/66785) — Comprehensive revision of facility licensure requirements at 9 CFR 108
• August 1990 (55 FR 35562) — Initial regulatory framework for genetically engineered veterinary biologics, creating the foundation for today's recombinant and DNA vaccine pathways

Recent Developments

• 2024–2026: HPAI vaccine licensing push. The HPAI H5N1 outbreaks that devastated U.S. poultry (over 100 million birds affected since 2022) and spread into dairy cattle herds in 2024 prompted serious policy debate about licensing avian influenza vaccines for use in commercial poultry. CVB has been evaluating candidate products; any approved HPAI vaccine must clear the full VSTA licensing pathway, including efficacy challenge studies and serial batch release testing. USDA has indicated it would conditionally approve vaccines under emergency provisions if needed.
• 2025: Livestock biologic supply chain scrutiny. As part of broader supply-chain security reviews, USDA APHIS examined the extent to which U.S. commercial livestock vaccine supply depends on foreign-manufactured active pharmaceutical ingredients and finished products. The import permit system at 9 CFR 104 became a focal point for discussions about domestic biologics manufacturing capacity.
• 2025: Oral rabies vaccine program expansion. APHIS continued expanding the oral wildlife rabies vaccination (ORV) zone in the eastern United States, distributing approximately 14 million vaccine baits annually. The program — using Raboral V-RG and ONRAB, both CVB-licensed recombinant products — is one of the largest ongoing applications of genetically engineered animal biologics in the world.
• April 2026: Pseudorabies confirmed in Iowa and Texas swine herds. APHIS confirmed pseudorabies (Aujeszky's disease) detections in commercial swine herds in Iowa and Texas — the first domestic detections in decades. Pseudorabies was declared eradicated from the U.S. swine population in 2004; these detections triggered emergency response under APHIS's swine health programs (see Swine Health Protection) and renewed attention to surveillance and potential CVB-licensed diagnostic biologics. (Source: APHIS press release, Apr. 30 2026.)
• May 2026: APHIS leadership restructuring. APHIS announced significant leadership changes across its Veterinary Services and other divisions — potentially affecting CVB operations and regulatory priorities. Stakeholders in the veterinary biologics industry are monitoring for any changes in licensing turnaround times or policy emphasis. (Source: APHIS agency announcement, May 2026.)
• May 2026: Multi-agency dog welfare enforcement action. USDA, DOJ, DHS, and HHS launched a coordinated enforcement initiative targeting chronic dog welfare violators under the Animal Welfare Act — an enforcement area that intersects with APHIS's licensing and inspection authorities, including for establishments that may also handle biological products used in dogs. (Source: APHIS press release, May 11 2026.)

Pending Legislation

• H.R. 2868 (119th Congress, Rep. Sarah McBride D-DE, introduced Apr. 10 2025, status: introduced) — Would fund land-grant university research on HPAI vaccines, poultry farm biosecurity practices, and the market effects of large-scale poultry vaccination. Directly targets CVB's licensing pipeline for avian influenza biologics. See also USDA Animal Health and Disease Research Grants for the existing grant framework this bill would expand.
• H.R. 1725 (119th Congress, Sen. Chuck Grassley R-IA, introduced May 13 2025, status: introduced) — Would create new health certification, identification, and permit requirements for dogs imported into the United States, tighten transfer requirements at ports of entry, centralize records, and allow fees to fund verification — relevant to APHIS import permit authority under 9 CFR 104.

Pending Action

Related Pages

CVB program siblings — the other three pillars of the 9 CFR 101–124 framework:

• APHIS Veterinary Biologic Facility Requirements — detailed facility design and equipment rules at 9 CFR 108
• APHIS Veterinary Biologic Labeling and Records — label approval and recordkeeping requirements at 9 CFR 112 and 116
• APHIS Veterinary Biologic Patent Term — patent term restoration specific to veterinary biologics

APHIS disease control programs that use these licensed biologics:

• Animal Health Protection — APHIS authority over animal disease eradication and interstate movement programs
• APHIS Animal and Bird Import Quarantine — quarantine controls that interact with the import permit system at 9 CFR 104
• APHIS Recognition of Animal Health Regions — how foreign disease-status determinations shape import permit requirements
• Swine Health Protection — Garbage Feeding Restrictions — disease prevention program for swine, intersects with CVB diagnostic biologics in outbreak response

Research and funding:

• USDA Animal Health and Disease Research Grants — federal grant program funding the basic research that underlies new biologics licensing applications

Parallel frameworks in human and device regulation:

• FDA Blood and Biologics Standards — parallel framework for human biological products (FDA/CBER)
• FDA Medical Device Classifications — parallel framework for human medical devices